Starling Oncology, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Starling Oncology, Inc. (DFPH) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $7.53 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-06
- Starling Oncology, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$3.29M.
- Starling Oncology, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$9.93M, a 486.83% decline year-over-year.
- Starling Oncology, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $2.57M, a 107.02% increase year-over-year.
- Starling Oncology, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $1.24M.
- Starling Oncology, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$16.10M, a 199.52% decline from fiscal 2024.
- Starling Oncology, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $16.18M, a 16.93% decline from fiscal 2023.
- Starling Oncology, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $19.48M.
- Starling Oncology, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$101.16M, a 192.66% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 2 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $7.53M 10-Q · filed 2026-08-06 | ||||||||
| 2026-03-31 | -$3.29M 10-Q · filed 2026-05-07 | ||||||||
| 2025-12-31 | -$16.10M 10-K · filed 2026-03-12 | ||||||||
| 2025-09-30 | -$22.01M 10-Q · filed 2025-11-13 | ||||||||
| 2025-06-30 | -$19.38M 10-Q · filed 2026-08-06 | ||||||||
| 2025-03-31 | -$9.93M 10-Q · filed 2026-05-07 | ||||||||
| 2024-12-31 | $16.18M 10-K · filed 2026-03-12 | ||||||||
| 2024-09-30 | $13.91M 10-Q · filed 2025-11-13 | ||||||||
| 2024-06-30 | $2.94M 10-Q · filed 2025-08-13 | ||||||||
| 2024-03-31 | $2.57M 10-Q · filed 2025-05-14 | ||||||||
| 2023-12-31 | $19.48M 10-K · filed 2025-03-26 | ||||||||
| 2023-09-30 | $13.53M 10-Q · filed 2024-11-13 | ||||||||
| 2023-06-30 | $14.88M 10-Q · filed 2024-08-13 | ||||||||
| 2023-03-31 | $1.24M 10-Q · filed 2024-05-14 | ||||||||
| 2022-12-31 | -$101.16M 10-K · filed 2024-03-28 | ||||||||
| 2022-09-30 | -$53.75M 10-Q · filed 2023-11-08 | ||||||||
| 2022-06-30 | -$50.97M 10-Q · filed 2023-08-09 | ||||||||
| 2022-03-31 | -$19.64M 10-Q · filed 2023-05-10 | ||||||||
| 2021-12-31 | $109.18M 10-K · filed 2023-03-16 | ||||||||
| 2021-09-30 | $5.53M 10-Q · filed 2022-11-09 | -$712.12K 10-Q · filed 2021-11-08 | |||||||
| 2021-06-30 | $9.17M 10-Q · filed 2022-08-09 | -$296.26K 10-Q · filed 2021-08-16 | |||||||
| 2021-03-31 | $21.41M 10-Q · filed 2022-05-10 | -$343.66K 10-Q · filed 2021-05-28 | |||||||
| 2020-12-31 | $3.55M 10-K · filed 2022-03-11 | $891.99K 10-K · filed 2021-03-30 | |||||||
| 2020-09-30 | $973.57K 10-Q/A · filed 2021-12-14 | ||||||||
| 2020-06-30 | $1.08M 10-Q · filed 2021-08-16 | ||||||||
| 2020-03-31 | $1.48M 10-Q · filed 2021-05-28 | ||||||||
| 2019-12-31 | $25.00K 10-K/A · filed 2021-12-14 |